Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy
Joint Authors
Himeno, Tatsuhito
Kamiya, Hideki
Naruse, Keiko
Kondo, Masaki
Nakamura, Jiro
Asano, Saeko
Hayami, Tomohide
Motegi, Mikio
Inoue, Rieko
Nakai-Shimoda, Hiromi
Miura-Yura, Emiri
Morishita, Yoshiaki
Tsunekawa, Shin
Kato, Yoshiro
Kato, Koichi
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-11-18
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Distal sensory-motor polyneuropathy is one of the most frequent diabetic complications.
However, few therapies address the etiology of neurodegeneration in the peripheral nervous systems of diabetic patients.
Several metabolic mechanisms have been proposed as etiologies of this polyneuropathy.
In this study, we revisited one of those mechanisms, the polyol pathway, and investigated the curative effects of a novel strong aldose reductase inhibitor, ranirestat, in streptozotocin-induced diabetic rats with preexisting polyneuropathy.
Twelve weeks after the onset of diabetes, rats which had an established polyneuropathy were treated once daily with a placebo, ranirestat, or epalrestat, over 6 weeks.
Before and after the treatment, nerve conduction velocities and thermal perception threshold of hindlimbs were examined.
After the treatment, intraepidermal fiber density was evaluated.
As an ex vivo assay, murine dorsal root ganglion cells were dispersed and cultured with or without 1 μmol/l ranirestat for 48 hours.
After the culture, neurite outgrowth was quantified using immunological staining.
Sensory nerve conduction velocity increased in diabetic rats treated with ranirestat (43.3±3.6 m/s) compared with rats treated with placebo (39.8±2.3).
Motor nerve conduction velocity also increased in the ranirestat group (45.6±3.9) compared with the placebo group (38.9±3.5).
The foot withdrawal latency to noxious heating was improved in the ranirestat group (17.7±0.6 seconds) compared with the placebo group (20.6±0.6).
The decrease in the intraepidermal fiber density was significant in the diabetic placebo group (21.6±1.7/mm) but not significant in the diabetic ranirestat group (26.2±1.2) compared with the nondiabetic placebo group (30.3±1.5).
Neurite outgrowth was promoted in the neurons supplemented with ranirestat (control 1446±147 μm/neuron, ranirestat 2175±149).
Ranirestat improved the peripheral nervous dysfunctions in rats with advanced diabetic polyneuropathy.
Ranirestat could have potential for regeneration in the peripheral nervous system of diabetic rats.
American Psychological Association (APA)
Asano, Saeko& Himeno, Tatsuhito& Hayami, Tomohide& Motegi, Mikio& Inoue, Rieko& Nakai-Shimoda, Hiromi…[et al.]. 2019. Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy. Journal of Diabetes Research،Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1172853
Modern Language Association (MLA)
Asano, Saeko…[et al.]. Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy. Journal of Diabetes Research No. 2019 (2019), pp.1-7.
https://search.emarefa.net/detail/BIM-1172853
American Medical Association (AMA)
Asano, Saeko& Himeno, Tatsuhito& Hayami, Tomohide& Motegi, Mikio& Inoue, Rieko& Nakai-Shimoda, Hiromi…[et al.]. Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy. Journal of Diabetes Research. 2019. Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1172853
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1172853